# Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC

> **NCT02591615** · PHASE2 · COMPLETED · sponsor: **Alliance Foundation Trials, LLC.** · enrollment: 91 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** MK-3475
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02591615
- **Lead sponsor:** Alliance Foundation Trials, LLC.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2019-01-04
- **Final completion:** 2020-07-04
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2022-12-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02591615

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02591615, "Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02591615. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*